Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 trial of Dexdor for prolonged sedation in paediatric patients
2018-003063-64Phase 3
- Sponsor
- Orion Corporation
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dexmedetomidine in None and Not applicable (not a disease), sponsored by Orion Corporation. Primary endpoint: Percentage of patients requiring additional analgesics and sedatives.
02
Drugs
dexmedetomidine
03
Conditions
Not applicable (not a disease)
Beyond the preview
Go deeper on 2018-003063-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003063-64.